View Post

New approach uses single PET scan to personalize cancer treatment

In In The News by Barbara Jacoby

Source: Society of Nuclear Medicine and Molecular Imaging From: sciencedaily.com Researchers have developed a same-day, noninvasive positron emission tomography (PET)-based imaging approach to assess PD-L1 positive tumors, and the study is presented in the featured article of The Journal of Nuclear Medicine‘s March issue. A healthy immune system strikes a delicate balance between eradicating infections and cancers and not overreacting …

View Post

Cancer-fighting gene-editing tool to begin human trials in China

In In The News by Barbara Jacoby

From: rt.com It may be banned in the UK, but DNA editing technology will begin trials on humans in China next month in the hope of curing lung cancer. The technique known as ‘Crispr’ acts like a scissors, cutting out unwanted sections of DNA. A team of scientists at Sichuan University’s West China hospital in Chengdu will be the first …

View Post

ASCO 2016: Roche’s Latest Tecentriq Results Underline Potential to Dominate Bladder Cancer Market

In In The News by Barbara Jacoby

As explored in an abstract presented at the 2016 American Society of Clinical Oncology (ASCO) conference, the launch of Roche’s recently approved PD-1 immune checkpoint inhibitor Tecentriq (atezolizumab) will usher in a dramatic change in the treatment paradigm of metastatic bladder cancer, according to an analyst with research and consulting firm GlobalData. The company’s most recent bladder cancer report states …

View Post

Too Many ‘Me-Too’ Cancer Drugs? FDA Official Asks

In In The News by Barbara Jacoby

By: Deena Beasley, Reuters From: nbcnews.com A new type of cancer drug that takes the brakes off the body’s immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.S. regulator says too many companies are focused on the same approach. The therapies, designed to disable the PD-1 protein that tumors use to evade the …

View Post

Pfizer, Bristol revive cancer drugs that rev up immune system

In In The News by Barbara Jacoby

By: Bill Berkrot From: reuters.com Some of the most heralded new cancer drugs fight the disease by removing brakes on the immune system. Now a few leading drugmakers are paying attention to a second, opposing force: medicines that accelerate the immune system’s attack. Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first …

View Post

New drugs from Bristol, Merck at forefront of cancer meeting

In In The News by Barbara Jacoby

By Deena Beasley and Bill Berkrot From: reuters.com New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body’s immune system to fight cancer can be used. Results from key clinical trials will be presented starting Friday in Chicago at the annual meeting of the American Society of Clinical Oncology. …